The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2020. This month are two guidelines and one medtech innovation briefing that impact upon primary care.
The COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders guideline has been updated. It aims to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources. This update highlights the possible risk of adrenal crisis for patients on long-term corticosteroids.
The COVID-19 rapid guideline: arranging planned care in hospitals and diagnostic services guideline has been published. It aims to help healthcare professionals deliver efficient planned care while minimising the risk of COVID-19 in the context of increasing or decreasing local prevalence. It also aims to help patients make decisions about their planned care. It includes recommendations on social distancing and hand hygiene measures prior to planned care.
The Prontosan for acute and chronic wounds medtech innovation briefing has been published. This briefing notes that the intended place in therapy would be as an alternative to saline or water to cleanse wounds during dressing changes. The available evidence indicates that Prontosan is likely to be better than saline for treating acute and chronic wounds, but it is noted that the studies were of short duration and there could be significant resource implications depending on product type and quantity used.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Which SGLT-2 Inhibitor?||CKS Updates - July 2020 »|